Ziyu Zeng

This study identifies CDH3 as a key driver of basal-like prostate cancer and shows that CDH3-targeted therapies like ADCs and CAR T cells are effective in preclinical models.

This study compares 3D culture scaffolds for prostate cancer cells, finding scaffold-dependent differences in spheroid formation and gene expression, particularly in neuroendocrine markers.

The paper identifies a novel marker gene set, CDHu40, for neuroendocrine prostate cancer (NEPC) using gene expression and PPI network analysis, showing strong prognostic significance.